License

LegalZoom Launches Beneficial Ownership Information Report to Help Businesses Satisfy New Federal Mandate under the Corporate Transparency Act

Retrieved on: 
Thursday, January 4, 2024
License, Failure, Small business, Government, Beneficial ownership, Risk, Running, Financial Crimes Enforcement Network, Illegal drug trade, Treasury, Fraud, ID, Unitary state, LegalZoom, Cryptocurrency

1 choice in online small business formations, announced the release of its Beneficial Ownership Information Report, a new addition to LegalZoom's ecosystem of compliance services.

Key Points: 
  • 1 choice in online small business formations, announced the release of its Beneficial Ownership Information Report, a new addition to LegalZoom's ecosystem of compliance services.
  • The new service helps customers satisfy the federally mandated beneficial ownership information reporting rule under the Corporate Transparency Act, which went into effect on January 1, 2024.
  • LegalZoom’s Beneficial Ownership Information Report service is available as a one-time filing to help customers avoid noncompliance and consequences.
  • To learn more about LegalZoom’s offerings, including its Beneficial Ownership Information Report service, please visit LegalZoom.com .

Tudor Gold Maintains Its Prior Rights as Mineral Tenure Owners

Retrieved on: 
Monday, November 20, 2023
Carbon, Maker, Seabridge Gold, KSM, Water, News, MTT, Letter, Ministry, Seabridge, LOO, License, Land Act, Communication, Gold, Mining

Tudor Gold shall oppose any steps by Seabridge Gold Inc. in any way to interfere with the mineral tenures of Tudor Gold Corp.

Key Points: 
  • Tudor Gold shall oppose any steps by Seabridge Gold Inc. in any way to interfere with the mineral tenures of Tudor Gold Corp.
  • As matters stand today, Seabridge Gold Inc. cannot construct the MTT Tunnels and to the extent Seabridge has been given authorization by the Licence of Occupation to enter onto the mineral tenures of Tudor Gold, those rights are expressly subject to the prior rights of Tudor Gold.
  • Geo., President & CEO of Tudor Gold Corp. comments: "Tudor Gold will not allow Seabridge Gold to destroy Tudor Gold's newly discovered resource to allow access for the MTT tunnels across Tudor Gold mineral claims.
  • As provided for in the Licence of Occupation of Seabridge Gold, that Licence is subject to the prior rights of Tudor Gold to it mineral tenures.

Else Nutrition and Danone Enter Into a Binding Multi-Stage Collaboration

Retrieved on: 
Monday, November 13, 2023
License, TSX, BABY, LOI, Water, Party, Letter

Vancouver, British Columbia--(Newsfile Corp. - November 13, 2023) - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL) ("Else" or the "Company"), is pleased to announce that it has agreed to a multi-staged collaboration with Danone S.A., a worldwide leading company specializing in fresh dairy products, plant-based, water and specialized nutrition.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - November 13, 2023) - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL) ("Else" or the "Company"), is pleased to announce that it has agreed to a multi-staged collaboration with Danone S.A., a worldwide leading company specializing in fresh dairy products, plant-based, water and specialized nutrition.
  • Else and Danone signed a letter of intent ("LOI") on November 13, 2023 providing for a multi-stage collaboration subject to the finalization of certain commercial terms.
  • The LOI was entered into following Danone having completed extensive due diligence.
  • At the first stage of the collaboration, Else and Danone will enter into a License Agreement whereby Else's products, which are plant based, soy-free and supported by clinical evidence, shall be included in Danone's specialized nutrition portfolio and manufactured, marketed and commercialized by Danone.

GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox

Retrieved on: 
Tuesday, December 19, 2023
Mpox, HHS, Infection, Immune system, Biotechnology, NIAID, Virus, License, Vaccine, Patent, Disease, City, COH, GeoVax, COVID-19, Cancer, Smallpox, Bangladesh Technical Education Board, HIV, SARS-CoV-2, Orthopoxvirus, NIH, Immunization, MVA

The amendment expands GeoVax’s commercial license to include Mpox and smallpox as additional indications.

Key Points: 
  • The amendment expands GeoVax’s commercial license to include Mpox and smallpox as additional indications.
  • Modified Vaccinia Ankara (MVA) is the vaccine currently used and stockpiled in the U.S. Strategic National Stockpile for immunization against the Mpox and smallpox viruses.
  • The addition of the Mpox and smallpox indications to our NIAID License Agreement complements GeoVax’s license agreement with COH for GEO-CM04S1, which we also recently amended to obtain development and commercialization rights against orthopoxviruses in addition to SARS-CoV-2.
  • For those regions/populations where Mpox and/or smallpox may be of a concern, we believe our COVID-19 vaccine will be a better choice.”

FDCTech Provides Updates on the Definitive Agreement for the Acquisition of Alchemy Group Companies and Direct Investment

Retrieved on: 
Thursday, December 7, 2023
ADS, MFSA, Law, The Company, Companies House, DMCC, Companies Act, Acquisition, FCA, Education, Common stock, Financial Conduct Authority, ETF, Bank statement, License, OTC, Contract for difference, Environment, Security (finance)

Irvine, CA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- FDCTech, Inc. ("FDC" or the "Company," OTCQB: FDCT), a fintech-driven company specializing in buying and integrating small to mid-size legacy financial services companies, today announced that the Company's Directors have approved the shareholders' actions ("Actions") from holders of approximately 89.01% of the 333,584,729 shares of Company stock issued and outstanding.

Key Points: 
  • The Company will receive $5,500,000 in direct investment from Alchemy Prime Holdings Shareholder for Common Stock valued at $0.11 per share.
  • Series A Preferred Investment: Alchemy Prime Holdings shareholders will provide the Company $2,500,000 in direct investment for Series A preferred shares, valued at $1.00 per share, totaling 2,500,000 shares.
  • The Company's acquisition involves purchasing shares of Alchemy UK and Alchemy Malta from Alchemy Prime Holdings Limited and its sole shareholder, Gope S. Kundnani.
  • Mr. Kundnani is a related and affiliated party with a controlling interest in the Company, Alchemy UK and Alchemy Malta.

Xlife Sciences AG paves the way for the next successful out-licensing and announces cooperation with Quant Biomarkers AG for the development of advanced biomarkers for kidney diseases

Retrieved on: 
Wednesday, December 20, 2023
Chronic kidney disease, IP, Kidney, Kidney failure, Kidney disease, Disease, Patient, Dialysis, CKD, Biomarker, Partnership, License, Health, Gesellschaft mit beschränkter Haftung, Pharmaceutical industry

Subsequent therapy slows the progression towards dialysis or kidney replacement, but does not lead to a curation of the disease.

Key Points: 
  • Subsequent therapy slows the progression towards dialysis or kidney replacement, but does not lead to a curation of the disease.
  • Xlife Sciences AG, through its portfolio company x-kidney diagnostics GmbH, has identified biomarkers that predict kidney failure at its pre-clinical stages.
  • Concurrently, Quant Biomarkers AG is actively pursuing intellectual property rights for specific combinations of kidney biomarkers, intending to use them for both diagnostic and prognostic purposes.
  • Oliver R. Baumann, CEO of Xlife Sciences AG, stated «Our collaboration with Quant Biomarkers AG represents a pivotal moment in our mission to transform healthcare through innovation.

CryptoBlox Signs Definitive Agreement to License Modular Renewable Energy Powered Mining Infrastructure Patent Rights for Four Years

Retrieved on: 
Monday, November 20, 2023
Crypto, Canadian Securities Exchange, Indian stock exchange, CSE, WIPO, Wind, License, Patent, Cryptocurrency

Crypto Green holds the rights to a patent application submitted with the International Bureau of WIPO (the “Patent Rights”) respecting the Renewable Energy Powered Crypto Mining Technology.

Key Points: 
  • Crypto Green holds the rights to a patent application submitted with the International Bureau of WIPO (the “Patent Rights”) respecting the Renewable Energy Powered Crypto Mining Technology.
  • The License is a significant step towards further expanding CryptoBlox’s off-grid, alternative energy powered digital asset mining infrastructure.
  • The License was negotiated at arm’s length and is not expected to result in a change of control of CryptoBlox.
  • A finder’s fee of 2,800,000 Common Shares, representing 7% of the number of Common Shares issuable pursuant to the License, will be payable to the party that introduced Crypto Green to the Company.

Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer

Retrieved on: 
Friday, November 17, 2023
License, Therapy, Research, LNP, POZ, Contributor License Agreement, RNA, Pharmaceutical industry, Pfizer

HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a privately held, clinical stage biotechnology company focused on developing its proprietary POZ Platform TM drug delivery technology, including POZ lipid nanoparticle (LNP) delivery systems for RNA-based therapeutics, today announced Serina has entered into a License Agreement under which Pfizer Inc. will license, on a non-exclusive basis, Serina’s POZ polymer technology.

Key Points: 
  • HUNTSVILLE, AL, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (Serina), a privately held, clinical stage biotechnology company focused on developing its proprietary POZ Platform TM drug delivery technology, including POZ lipid nanoparticle (LNP) delivery systems for RNA-based therapeutics, today announced Serina has entered into a License Agreement under which Pfizer Inc. will license, on a non-exclusive basis, Serina’s POZ polymer technology.
  • “We are excited about the license to Pfizer for its use of the POZ polymer technology in initial research and development activities,” stated Dr. Milton Harris, Executive Board Chair at Serina Therapeutics.
  • “The license agreement represents an important milestone for Serina.”

FDCTech's Quarterly Release for the Third Quarter (FY23 Q3) Results

Retrieved on: 
Tuesday, November 14, 2023
ALGO, Companies Act, ETF, MFSA, The Company, Law, Malta Financial Services Authority, Contract for difference, License, Hand, Growth, Financial condition report, OTC, Education, Clothing, Cryptocurrency, Financial services

Irvine, CA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- FDCTech, Inc. ("FDC" or the "Company," OTCQB: FDCT), a fintech-driven company specializing in buying and integrating small to mid-size legacy financial services companies, today announced the following results for the three and nine months ending September 30, 2023, as compared to the corresponding period of September 30, 2022:

Key Points: 
  • The Company reported a net income of $638,084 and $1,366,777 for the three and nine months ending September 30, 2023.
  • The gross margin generated for the three months ending September 30, 2023, and 2022 were $2,311,165 and $198,702, an increase of 1,063% from the previous period.
  • Please visit our SEC filings or the Company's website for more information on the full results and management's plan.
  • A dedicated team of qualified financial planners brings expertise and a commitment to servicing metropolitan and regional practices across Australia.

AppTech Payments Corp. Reports Third Quarter 2023 Results

Retrieved on: 
Tuesday, November 14, 2023
Acquisition, License, Fintech, Bank statement, Silicon, Mobile payment, Payment, Movement, Independent software vendor, Micro ISV, Partnership, Growth, API, Visa, SMS, Environment, Mastercard, Beauty salon, Mobile phone, Broadnet Holdings BV

CARLSBAD, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AppTech Payments Corp. (NASDAQ: APCX), a pioneering Fintech company powering frictionless commerce between business-to-business and business-to-consumer, today announced results for its third quarter ended September 30, 2023.

Key Points: 
  • CARLSBAD, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AppTech Payments Corp. (NASDAQ: APCX), a pioneering Fintech company powering frictionless commerce between business-to-business and business-to-consumer, today announced results for its third quarter ended September 30, 2023.
  • Revenue was approximately $140 thousand for the three months ended September 30, 2023, representing an increase of 22% from the same prior-year quarter.
  • Revenue was approximately $363 thousand for the nine months ended September 30, 2023, representing an increase of 6% from the same prior-year period.
  • “The third quarter represented a transformational period of AppTech,” said Luke D’Angelo, Chairman & CEO of AppTech.